ArticleBMC cardiovascular disorders2025
Usefulness of platelet mass index in the prediction of angiographic no-reflow in patients with acute ST-segment elevation myocardial infarction.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Endothelial Activation and Stress Index (EASIX) as a novel index associated with no-reflow phenomenon in STEMI: a bi-center retrospective study.BMC cardiovascular disorders · 2026Article
- Dual-pathway model of IL-6 and HSP22/HSP27 dynamics predicts post-PCI MACE in STEMI patients.BMC cardiovascular disorders · 2025Article
- Mean platelet volume and long-term cardiovascular outcomes in patients with type 2 diabetes mellitus.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveNo-reflow phenomenon (NR) is a serious complication with increased morbidity and mortality in percutaneous coronary interventions in patients with acute ST-segment elevation myocardial infarction (STEMI). Studies on the relationship between the NR and mean platelet volume (MPV) and platelet count (PLT) are controversial. Platelet mass index (PMI) is a novel inflammation and platelet index, calculated as PLT multiplied by MPV. So, it would be prudent to assume that a high PMI is likely to be associated with NR. PMI's low cost and rapid availability may aid NR risk stratification. Our aim was to assess the relationship between PMI and no-reflow in acute STEMI patients.
methodsA total of 212 acute STEMI patients were enrolled in this retrospective study and the patients were stratified into two subgroups as no-reflow group (n = 45) and reflow group (n = 167). Patient data regarding demographics, clinical, angiographic and laboratory parameters were retrieved from the digital hospital archives. No-reflow was defined angiographic thrombolysis in myocardial infarction (TIMI) flow grade ≤ 2. PMI was calculated as platelet count multiplied by mean platelet volume (MPV).
resultsMean age of the no-reflow and reflow groups was 59.3 ∓ 8.6 and 59.1 ∓ 12.6 years, respectively (p > 0.05). PMI was greater in the no-reflow group [2585(2278-3000) vs. 2054(1594-2344), respectively, p < 0.001]. PMI was correlated with WBC count (r = 0.290, p < 0.001), Hemoglobin (r=-0.281, p < 0.001), neutrophil count (p = 0.303, p < 0.001), platelet count (r = 303, p < 0.001), MPV (r = 0.195, p = 0.006), platelet distribution width (p = 0.215, r = 0.002), and PCT (r = 0.970, p < 0.001), and Syntax score-2 (r = 0.162, p = 0.024). In mulvariate logistic regression analysis, PMI [OR: 1.008(1.003-1.012), p = 0.001], age [OR: 1.111 (1.036-1.253), p = 0.007], and WBC count [OR: 0.018(0.001-0.581), p = 0.024] were independently associated with NR.
conclusionPMI has been a simple and readily available parameter that could be a promising indicator to estimate NR in patients with acute STEMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.